Skip to main content
Hematology and Oncology
ALL Specialities
ALL Specialities
/
Hematology and Oncology
Blood & Cancer Podcast
CME
Diseases & Conditions
Nonmalignant Hematologic Disorders
Anemia
Bleeding Disorders
Thrombosis
Breast Cancer
CNS/Brain Cancer
Gastrointestinal Cancer
Genitourinary Cancer
Renal Cell Carcinoma
Gynecologic Cancer
Head & Neck/Thyroid Cancers
Leukemia, Myelodysplasia, Transplantation
ALL
AML
Cellular Therapy
CLL
CML
Myelodysplastic Syndrome
Transplantation
Lung Cancer
Lymphoma & Plasma Cell Disorders
B Cell Lymphoma
Follicular Lymphoma
Hodgkin Lymphoma
Mantle Cell Lymphoma
Multiple Myeloma
Non-Hodgkin Lymphoma
T Cell Lymphomas
Melanoma
Nonmelanoma Skin Cancer
Sarcoma and GIST
COVID-19 Updates
Conference Coverage
Conference Coverage
Durvalumab could offer option for difficult-to-treat NSCLC
Publish date:
December 8, 2016
op@frontlinemedcom.com
Pages
« first
1
2
Recommended Reading
Checkpoint inhibitors for lung cancer figure prominently at WCLC 2016
MDedge Hematology and Oncology
Centers of excellence program raises quality bar in lung cancer management
MDedge Hematology and Oncology
VIDEO: Decision aids can relay relative risks to lung cancer patients
MDedge Hematology and Oncology
Nivolumab plus ipilimumab shines as first-line in advanced NSCLC
MDedge Hematology and Oncology
VIDEO: Checkpoint inhibitors show few efficacy, safety differences
MDedge Hematology and Oncology
KRAS-targeted T-cell therapy derails metastatic cancer
MDedge Hematology and Oncology
Ganetespib fails to hit mark in phase III NSCLC trial
MDedge Hematology and Oncology
‘Vanishing’ role forecast for whole-brain irradiation for NSCLC metastases
MDedge Hematology and Oncology
VIDEO: Pivotal results nail osimertinib’s role in NSCLC
MDedge Hematology and Oncology
Pembrolizumab proves promising for treating advanced SCLC
MDedge Hematology and Oncology
Lung Cancer
All Specialties
